Depression

• What are Therapeutic Market Outlooks?
• Available Reports
• Pricing and Deliverables
• TMO Sample Pages

Tables and Figures - Depression

• Page 3: Depression Progression Chart
• Page 3: Common Antidepressant Uses
• Page 4: U.S. Prevalence Rates
• Page 6: AVOS Population Projections by Year
• Page 7: U.S. Depression Patient Population Model
• Page 11: U.S. Depression Market Model, 2003-2013
• Page 12: U.S. Depression Market Model, 2003-2013, continued
• Page 13: Primary Care Physician Patient Flow
• Page 14: Psychiatrist Patient Flow
• Page 16: Antidepressant Product Differentiation
• Page 17: Marketed Generics
• Page 18: Weighted Physician Product Ratings
• Page 18: Psychiatrist versus PCP Product Ratings
• Page 18: Share of Prescriptions, 5-Year Forecasted Trend, and Major Trend Drivers
• Page 21: Marketed Products
• Page 23: Timeline of Major Marketed Events
• Page 24: Effexor Franchise/venlafaxine Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 26: Effexor XR Additional Indications
• Page 27: Lexapro/escitalopram Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 28: Lexapro Additional Indications
• Page 29: Cymbalta Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, Commercial Strength, and Cymbalta NRx and TRx
• Page 31: Cymbalta Additional Indications
• Page 32: Wellbutrin Franchise/bupropion Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 34: Wellbutrin Additional Indications, Wellbutrin XL Additional Indications, and Wellbutrin SR Additional Indications
• Page 35: Paxil Francise/paroxetine Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 36: Paxil Additional Indications and Paxil CR Additional Indications
• Page 37: Zoloft/sertraline Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 38: Zoloft Additional Indications
• Page 39: Prozac/fluoxetine Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, and Commercial Strength
• Page 40: Prozac Additional Indications
• Page 41: Celexa/citalpram Revenue Model, U.S. Market Share Forecast, U.S. Revenue Forecast, Commercial Strength, and Additional Indications
• Page 42: Gepirone-ER Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 43: Gepirone-ER Additional Indications
• Page 44: Saredutant/SR 48968 Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 45: Saredutant Additional Indications
• Page 46: Amibegron/SR 58611 Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 47: Amibegron Additional Indications
• Page 48: Agomelatine (Valdoxan/Thymanax) Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 49: Agomelatine Additional Indications
• Page 50: Pristiq (desvenlafaxine succinate)/DVS-233 Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 52: Pristiq Additional Indications
• Page 53: Vilazodone Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 54: Vilazodone Revenue Model, U.S. Market Share Forecast, and U.S. Revenue Forecast
• Page 54: Vilazodone Additional Indications
• Page 55: Clinical Success Rates of Antidepressant Agents: 1990-Present
• Page 57: Drugs in Development